NCT04955834

A Clinical Study of Insulin Degludec Injection in Subjects With Type 2 Diabetes

A Multicenter, Randomized, Open-label, Parallel-controlled Phase III Clinical Study to Compare the Efficacy and Safety of Insulin Degludec Injection Versus Tresiba® in Subjects With Type 2 Diabetes

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 344 (estimated)
• Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This study is a multi-center, randomized, open-label, parallel, positive-controlled registered clinical study,to evaluate the efficacy and safety of insulin degludec injection developed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Conditions

• Type 2 Diabetes

Interventions

Type	Name	Description
DRUG	Insulin degludec injection	long-acting insulin
DRUG	Tresiba®	long-acting insulin

Timeline

• Start date: 2021-07-27
• Primary completion: 2025-12-31
• Completion: 2025-12-31
• First posted: 2021-07-09
• Last updated: 2021-09-21

Locations

2 sites across 1 country: China